black box warning for glp 1 warnings: Definition, medications, and more Management of Obesity in Patients

For patients with an A1C of 6.5% to 7.5%, metformin is the preferred initial agent, with GLP-1 receptor agonists, dipeptidyl-peptidase-4 (DPP-4) inhibitors, thiazolidinediones (TZDs), or an alpha-glucosidase inhibitor listed as viable alternatives

In 2022, a novel GLP-1 analog, semaglutide was introduced as an anti-obesity drug

Who Tends to Maintain Weight Successfully After Stopping GLP-1s Patients who do best after discontinuation often share common factors: They taper slowly rather than stopping abruptly They rebuild hunger awareness while still on medication They prioritize adequate protein intake They preserve lean muscle through resistance training They address sleep, stress, and hormonal health They maintain medical follow-up during the transition This is not about perfection

10.2147/PPA.S29716 [DOI] [PMC free article] [PubMed] [Google Scholar] Alves N

Start with lighter weights and focus on proper form to avoid injury

4b and Supplementary Table 6)